The objectives of this study were to a) replicate our prior finding of a decreased number (Bmax) of platelet a2-adrenoreceptors in panic disorder, b) determine if binding is also decreased in asymptomatic first-degree relatives of panic patients (known to be at increased risk for developing panic), and c) evaluate the effect of treatment on the presumptive decrease in binding (ie, is the decrease a state or a trait marker for panic?). Panic patients had clonidine and yohimbine platelet-binding assays, symptom ratings, and measurement of lying and standing plasma epinephrine, norepinephrine, systolic and diastolic blood pressure, and heart rate before treatment, after approximately 2 months of medication (fluoxetine, tricyclics, or alprazolam) and/or cognitive behavioral treatment, and after symptom remission while drug free; normal subjects had determinations of the same measures at approximately the same time intervals. Relatives of both groups had one determination only of all measures. Tritiated clonidine binding was decreased and lying heart rate was increased in patients before treatment. Magnitude of binding decrease was correlated with symptom severity and standing norepinephrine. No binding abnormality was seen in first-degree relatives of patients. Treatment increased clonidine binding in patients. Both patients and relatives of patients showed significantly increased standing plasma norepinephrine in comparison to controls. There is a state-related decrease in binding, associated with symptom severity and norepinephrine, in panic disorder. Abnormal reactivity of norepinephrine to standing might be a marker for increased likelihood of panic development in individuals at risk.
INTRODUCTION
Systemic adrenergic abnormalities have been reported in association with stress and with a number of psychiatric and medical disorders (1) . Adrenergic dysregulation appears especially salient to several of the anxiety disorders, especially panic disorder (2). Most of these studies have evaluated individuals before treatment while symptomatic; only a few have reported changes during and/or after treatment and symptom remission as well (3, 4).
Adrenergic functioning in the periphery has been studied in several ways, such as measurement of catecholamines or their metabolites and monitoring of hemodynamic variables. For example, many groups have studied plasma norepinephrine and epinephrine and the metabolite 3-methoxy-4-hydroxy-phenethyleneglycol (MHPG) in panic patients (2, 5-16). We have reviewed these studies (2, 16). A completely clear picture does not emerge. We have suggested that:
. . . if a patient is in a truly basal state, there is either no increase in catecholamines or only small catecholamine elevations in panic patients. Patients, however, may be more reactive to various 'stressful' circumstances (e.g., venipuncture, postural change, and ambulation) and may have a response that exceeds the response of control subjects. . . although not all studies have reported this (2) Because adrenergic systems are acutely responsive to a variety of stimuli and because activity levels can fluctuate rapidly, attempts have been made to identify measures that might reflect more stable aspects of these systems. Furthermore, efforts have been made to find easily measurable peripheral markers that reflect some aspect of central nervous system adrenergic activity. Binding of adrenergic ligands to peripheral tissues is one such approach. Blood components such as lymphocytes and platelets are most commonly used, in part because of their accessibility, but also because they have been proposed as models of neuronal tissue (17, 18) .
Changes in drug-free, pretxeatment binding of platelet a2-adrenergic receptors in panic disorder have been reported previously, although not all
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studies have found abnormalities. In two prior studies of patients with panic disorder, we found decreased binding; one study found a decrease with the antagonist tritiated yohimbine but not with the partial agonist tritiated clonidine, and the other found decreases with both ligands (9, 11). Another group (14, 19) also reported decreased yohimbine binding in panic disorder, but two other groups did not (20, 21) . People with both panic and comorbid depression also had decreased tritiated clonidine binding (22) . Other investigators have found different results (23, 24) , but because they used different ligands, the studies are not completely comparable. In addition to changes in panic anxiety, Freedman et al. (25) reported a decrease in platelet a2-adrenergic receptors, as measured by yohimbine binding, in response to examination stress in medical students; magnitude of decrease was associated with magnitude of increases in plasma norepinephrine and reported anxiety.
Despite discrepancies in patterns of ligand binding abnormality, both of our prior studies found evidence for decreased binding in symptomatic patients with panic disorder. The present study was intended to extend these prior results and to begin to explore whether adrenergic binding abnormalities might represent trait markers for either active panic or panic vulnerability in people at high risk. We had three aims: a) to replicate our prior finding of decreased platelet a2-adrenergic receptor number (Bmax) as measured with tritiated clonidine and tritiated yohimbine in panic patients before treatment, b) to determine if there is any abnormality of binding, systemic catecholamines, or hemodynamic variables in the asymptomatic first-degree relatives of panic patients (individuals at high risk to develop the disorder) (26, 27) , and c) to determine the effect of treatment and symptom reduction on binding in panic patients, ie, to determine if the previously described binding abnormality is a state or a trait marker of panic disorder (28) . Both ligands (tritiated clonidine and tritiated yohimbine) were used because prior research has suggested that yohimbine, an antagonist, binds to the total population of platelet a2-adrenergic receptors and that clonidine, a partial agonist, binds to a subpopulation of the receptors, related to whether the receptors are in an "active" or an "inactive" (ie, "coupled'V'uncoupled," "high affinity'V'low affinity") state (29, 30) . In other words, yohimbine binding should relate to the total population of receptors present on the tissue being analyzed, and clonidine binding should reflect a subpopulation of receptors in the tissue that are involved in the production of a physiological response.
Determinations of anxiety symptoms, lying and standing plasma catecholamines (epinephrine and norepinephrine), heart rate, and systolic and diastolic blood pressures were done at the same times as the binding studies. Relatives of patients and controls were also studied to determine for both patients and control subjects if there are significant correlations with their respective first-degree relatives for the dependent variables.
METHODS

Subjects
Patients with panic disorder (with or without agoraphobia), normal healthy controls, and healthy first-degree relatives of both groups were studied; no more than one relative of a given patient or control subject participated. Relatives of patients had no symptoms of panic attacks. Patients were diagnosed using a structured interview and DSM-III-R criteria (31); all reached criteria for panic disorder at the time of initial study (including having had at least four attacks in the prior 4 weeks, of which at least two must have been full symptom attacks) and were drug free for at least 2 weeks before the study. No patient reached criteria for any affective disorder, and no control subject or relative reached criteria for any Axis-I disorder as determined with the structured clinical interview for DSM-III-R SCID-NP (SCID-nonpatient). All subjects were medically healthy, and no normal subject or relative was on any medication known to affect either adrenergic receptors or platelet number or function. Anxiety symptom severity at the time of initial evaluation was quantified by the Hamilton Anxiety Scale (Ham-A, 32), die Symptom Checklist-90-R (SCL-90-R, 33), and ratings of unexpected and situational panic attacks and anticipatory anxiety (34) . The Hamilton Depression Rating Scale (Ham-D, 35) was also administered at this time.
Design
The design of the study called for measurements of anxiety symptoms, platelet membrane a2-adrenergic receptor binding (Bmax: maximum number of binding sites and Kd: apparent dissociation constant, for both tritiated clonidine and tritiated yohimbine), lying and standing plasma epinephrine and norepinephrine, lying and standing systolic and diastolic blood pressure, and lying and standing heart rate in all subjects. The design involved evaluation of as many patients and control subjects as possible (but not relatives) through the longitudinal study, including determinations on three separate occasions. The follow-up studies called for the ability and willingness of the subjects to return for repeat studies and required meeting strict improvement criteria for patients. Patients were studied initially before treatment (time 1). All of the dependent variables were also measured in control subjects and in first-degree relatives of patients and controls. Relatives were only studied once.
Many of the patients and controls subjects had a second determination (time 2). The second determination of all dependent variables occurred approximately 2 months after the first. For the patients, this was after 2 months of drug or behavioral treatment, with the type of treatment determined by clinical consensus between the patient and his or her treating clinician.
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Some of the patients and normals who had a second determination also had a third (time 3). For the patients, the third determination was done after the patient had experienced a sustained reduction of at least 75% in frequency and severity of panic attacks and anticipatory anxiety, while being drug free for at least 1 month. For normal subjects, the third determination was approximately 1 year after the first, to approximate the length of time between studies at times 1 and 3 for the patients. For the third determination, only binding parameters and symptoms were measured.
Procedure
To control for possible circadian effects (36) , all subjects were studied between 7:30 and 10:30 AM. At the time of arrival in the laboratory, each subject assumed a supine position and had a venous catheter inserted for blood sampling. After catheter insertion, the Ham-A and Ham-D rating scales were completed by one of the investigators (O.G.C.). After 20 minutes supine, an 80-ml blood sample was obtained. From this specimen, platelets were isolated for determination of platelet membrane a2-adrenergic receptor agonist and antagonist binding, and lying plasma catecholamines were determined.
After this specimen was obtained, subjects stood as a mild autonomic challenge (maintenance of blood pressure with change in posture), after which a 10-ml specimen was obtained to measure standing catecholamine levels. Blood pressure (determined with a stethoscope and sphygmomanometer) and heart rate (determined by palpation of the radial artery) were measured in the arm opposite from the catheter immediately before the lying and standing specimens were obtained.
Twenty four of the patients and all of the other subjects stood for 3 minutes before the standing specimens were obtained. Sixteen of the patients stood for 15 minutes; the subjects who stood for 15 rather than 3 minutes had also been participants in another study in which both patients and normal subjects stood for 15 minutes (11). Only platelet binding measures and lying norepinephrine are reported here for the group of patients studied at 15 minutes (epinephrine, blood pressure, and heart rate were not included); standing catecholamine and hemodynamic data are reported in this study only for the subjects who stood for 3 minutes.
Platelet membrane a2-adrenergic receptor binding assays were performed by our previously described method (37) . Assays were always performed on fresh membranes on the day on which they were obtained (never frozen). Specific binding of clonidine, a partial agonist for the platelet a2-adrenergic receptor, and yohimbine, an antagonist, were determined. Specific binding was approximately 85 to 90%. Estimates of the binding parameters (Bmax: fmoles/mg protein, and Kd: nM) for both ligands were made. Plasma for catecholamine assays was frozen at -80°C until assay. Catecholamines were determined by high performance liquid chromatography with electrochemical detection (38) . Binding assays and catecholamine determinations were always performed by individuals blind to the subjects' group status.
Data Analysis
Because different numbers of subjects were studied at different times, separate analyses of variance (ANOVA) were performed across subject groups at the different time points for the separate dependent variables (clonidine Bmax and Kd, yohimbine Bmax and Kd, anxiety severity ratings, and lying and standing epinephrine, norepinephrine, systolic blood pressure, diastolic blood pressure, and heart rate). Effects of different treatment modalities on binding parameters were evaluated with ANOVA at time 2. Repeated-measures ANOVA were used to test effects across times. Tests were done with log-transformed data when appropriate. Multivariate analysis of variance (MANOVA) was used to evaluate the potentially interacting effects of clonidine Bmax, standing norepinephrine, and gender. For all tests, significance was defined as p < .05; a trend was defined as p < .10. Significance levels were reported without adjustment for multiple tests.
Correlations among variables were assessed. Correlations were determined among all possible combinations of the Bmax for clonidine and yohimbine, both within and across time points for times 1 and 2. These correlations were performed to determine if there was an association between the total number of receptors and the subpopulation represented by clonidine binding. Binding parameters were also correlated with Ham-A scores, catecholamine levels, and hemodynamic variables. As a test of whether there is a familial (genetic?) contribution to the values of the binding parameters, these parameters were correlated for patients with their first-degree relatives and control subjects with theirs. Ham-A scores were correlated with Ham-D scores, obtained at the time of evaluation. Finally, multiple regression was used to determine the combined association of symptoms and norepinephrine levels with clonidine binding before treatment (time 1).
The first aim (above) was addressed by comparing the results of the binding parameters of patients vs. asymptomatic individuals at time 1. The second aim was addressed by comparisons of binding parameters and other dependent variables for the relatives of the patients. And the third aim was addressed by comparing patients to the control subjects at times 2 and 3. A number of other post hoc issues, such as the status of the catecholamine, hemodynamic, and symptom variables in patients vs. other subjects across the three times and a number of correlational questions, was also considered.
RESULTS
A total of 78 subjects were studied. The group size and gender breakdown were as follows: patients (male: 11, female: 29), normals (male: 7, female: 13), relatives of patients (male: 5, female: 4), and relatives of normals (male: 0, female: 9). Mean ages for the four groups, respectively, were 34.9, 28.4, 42.0, and 29.0 years. The mean age of panic onset was 24.8 years.
Despite efforts to study all patients and control subjects across all three time points, some attrition occurred. Attrition between time 1 and time 2 reflected both treatment drop-outs for patients and some withdrawal from the study for other reasons. Attrition from time 2 to time 3 mainly reflected the fact that many patients either did not attain the strict symptom improvement required or they relapsed during or soon after discontinuation of active treatment. In actual numbers, 27 of 40 of the patients and 9 of 20 of the control subjects were studied at time 2,
and, of these, 7 patients and 8 control subjects were also studied at time 3.
Symptom Ratings
As expected, at time of initial evaluation before treatment (time 1), patients were highly significantly more symptomatic than normal controls on several measures of anxiety symptomatology (Table 1) . Based on the results of the SCL-90-R, this anxiety severity level was comparable to a large sample of patients studied previously in this clinic (39) .
The mean Ham-D score for patients at evaluation was 14.3. No subject had a major depressive disorder. The correlation at evaluation between the Ham-D and the Ham-A was +0.910; thus, it is likely that this Ham-D score represents in large part rating of anxiety-related symptoms. Only the Ham-A results were analyzed further.
Symptoms of anxiety in patients decreased from time 1 to time 2 in response to treatment (Table 2 ). There were further decreases from time 2 to time 3 in the Ham-A and the anticipatory anxiety ratings. At time 3, the Ham-A rating was approximately 25% of the rating at time 1 and the anticipatory anxiety rating was approximately 15% of the rating at time 1. Across the three times, these decreases were both highly significant [p < .0005, repeated measures ANOVA).
Ligand Binding Comparisons
Comparing patients with control subjects (not including relatives) at time 1, including gender as well "Mean/standard deviation/number of subjects studied at time of evaluation. Ratings of relatives are included in the group of normal subjects and are not shown separately but were comparable to the ratings for the normal control subjects. "Unexpected" and "situational" are the mean number of panic attacks per week of each type. "Anticipatory" is a rating of amount of time during which anticipatory anxiety was present on a scale of 0 to 100% for the week before the rating. Significance ratings are for unpaired t tests. Data were not available for all subjects. <.001 a Mean/standard deviation. "Unexpected" and "situational" are the mean number of panic attacks per week of each type. "Anticipatory" is a rating of average anticipatory anxiety on a scale of 0 to 100% for the week before the rating. Significance rating are for repeatedmeasures ANOVA. Data were not available for all subjects.
as diagnosis as independent variables, there was a trend for patients to have lower clonidine Bmax (p < .10, ANOVA); the gender factor was not significant. For the Bmax for clonidine binding at time 1, an ANOVA across the normal subjects and the two relatives groups (without inclusion of patients) did not approach statistical significance (p = .42); therefore, because the binding data among groups were not significantly correlated (ie, were independent; see below), these three groups were combined to form one group of asymptomatic nonpatients for comparison to the patient group. In comparison with all of the asymptomatic subjects, patients had significantly lower clonidine binding (p = .05, ANOVA, Table 3 ). In this ANOVA, including gender and diagnosis, the gender factor was not significant, but the difference between patients and other subjects showed an even stronger difference (p < .03). Based on the estimated w 2 statistic (40), the diagnosis factor accounts for approximately 4% of the variance in the data at time 1. No significant differences were observed for yohimbine Bmax (Table 3) , and no differences for the dissociation constants (Kd) were observed for either ligand (not shown). Gender was also nonsignificant for the other binding measures.
Among the 40 patients, 19 were treated with medications (fluoxetine 2, tricyclic "antidepressant" 11, and alprazolam 6); the remaining 21 were treated with cognitive behavior techniques without medication. For the 27 of these 40 patients who were studied at time 2, there was a 10.5% increase from time 1 in the clonidine Bmax (p < .06, repeated measures ANOVA). Differences among treatment methods (drug vs. nondrug or among drugs) were observed for the clonidine Bmax at time 2, although they were not significant, as measured either as means at time 2 or as mean change from time 1 to time 2. For patients treated with drugs, the average binding across all drugs did not change significantly, and binding for those given tricyclic drugs actually deviation/number of subjects studied at each time. For both ligands, "all asymptomatic" includes normal subjects and both relatives groups. Patients were significantly lower than the aggregate group of all asymptomatic individuals at time 1 for clonidine binding (p = .05, and p < .03 if separated by gender, two-factor ANOVA); there was a trend for patients to be higher than normal subjects for clonidine binding at times 3 (p < .08, ANOVA).
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decreased more than 25%. Individuals treated without medications, however, demonstrated an increase in binding of more than 20%. Thus, if all patients were treated nonpharmacologically (thus avoiding the possible direct effects of tricyclics or other medication on receptor binding), the increase in binding from time 1 to time 2 would have been even greater than the increase that was actually observed. The decrease in clonidine binding observed with tricyclic drugs was not observed for yohimbine binding; there was no consistent difference for patients treated with vs. without medication for change in yohimbine binding from time 1 to time 2. The normal subjects also showed an increase in binding from time 1 to time 2 of comparable magnitude, however. Thus, because of unexpectedly low clonidine binding for some of the control subjects at time 1 and the increase from time 1 to time 2 for these control subjects, the change in binding from time 1 to time 2 observed in the patients cannot be ascribed unequivocally to clinical improvement.
Seven of the patients and eight of the control subjects were studied a third time; all patients were drug free and had substantially improved clinically at that time. The patients showed a substantial further increase in clonidine binding (Bmax) at that time [p < .09, repeated measures ANOVA for time 2 to time 3, Table 3 ), and the control subjects did not show an increase from time 2 to time 3. Comparing time 3 only, patients showed a trend for binding to be higher than for the normal subjects (p < .08, ANOVA); based on the estimated w 2 statistic, this difference accounts for approximately 16% of the variance in the data at time 3.
Ligand Binding Correlation To evaluate the relationships among the binding parameters themselves, correlations were determined among all possible combinations of the Bmax for clonidine and yohimbine at times 1 and 2. All were positive and significant except the clonidine binding at time 2 with the binding of both of the ligands at time 1 (Table 4) .
Symptom ratings were correlated with binding parameters. At time 1, for all subjects combined, the correlation of the clonidine Bmax with the Ham-A was -.270 and with the rating of anticipatory anxiety was -.281 (both p = .05). When these same correlations were calculated for patients only, the correlation coefficients were -.499 (p <
for all subjects with their first-degree relatives and separately for patients with their firstdegree relatives and normal subjects with their firstdegree relatives. For all subjects combined, the magnitudes of the coefficients ranged from +0.086 to +0.318; none was significant. Results for the patient and the normal subject groups done separately were comparable with the results of the combined group and again were not significant.
Catecholamines
Comparisons were performed for catecholamines; standing comparisons included only the patients who stood for 3 minutes (Table 5) . Across the four groups, at time 1 there was a significant difference for standing norepinephrine (Fig. 1 ). This was due to higher levels for both patients and relatives of patients than for the other two groups [p < .02, ANOVA); this difference remained, with the same significance level, when differences in log-transformed standing norepinephrine levels were compared. Based on post hoc tests, patients were significantly different than controls, and relatives of patients were different than both controls and relatives of controls. For the first two groups, there was a mean increase of 47% (44% for patients and 54% for relatives of patients) from lying to standing, and for the other two groups, the increase was only 21% (15% for normals and 29% for relatives of normals). Across the four groups, in addition to absolute values, there was a trend toward a significant difference [p < .08, ANOVA) for change scores (ie, the differ- 90.3/18.3/15 80.1/11/9 3 Mean/standard deviation/number of subjects studied at each time. Data, presented only for subjects who stood 3 minutes, were not available for all subjects at all time points. Lying heart rate was significantly higher in patients than in other subjects at time 1 (p < .05, ANOVA), and lying diastolic blood pressure showed a trend in the same direction (p < .06, ANOVA). See Figure 1 for standing norepinephrine presented separately for each of the four groups.
ence between lying and standing norepinephrine); the significance level was the same (p < .08, ANOVA) for a change-score comparison for patients vs. controls only (excluding relatives). The mean standing norepinephrine levels for the four groups were: patients 487 pg/ml, relatives of patients 628 pg/ml, controls 346 pg/ml, and relatives of controls 381 pg/ml. No other catecholamine differences were observed (Table 5) , and no gender differences were seen. Comparing patients with controls only (without inclusion of data from relatives), patients were significantly higher for absolute level (p < .03, ANOVA), and there was a trend in the same direction for change scores (standing minus lying, p < .08, ANOVA). Absolute values for standing levels showed more robust differences than change scores , and healthy first-degree relatives of the control subjects [Con-Rel, N = 9). There were no significant differences across lying levels; there was a significant difference across standing levels, with patients significantly greater than controls and relatives of patients significantly greater than both controls and relatives of controls. Only subjects who had both lying and standing levels are presented.
because lying levels were somewhat higher for patients and their relatives ( Fig. 1) . At time 1, standing norepinephrine was significantly negatively correlated with clonidine binding (r = -.389, p < .01). A significant correlation was also observed with standing norepinephrine and yohimbine binding (r = -.385, p < .01). No other significant correlations were observed for any catecholamine levels with any of the binding parameters. No significant correlations were observed for any of the catecholamine levels with any of the symptom ratings at time 1. Age was not significantly correlated with clonidine or yohimbine Bmax or Kd at time 1. There were trends for age to be significantly correlated with lying norepinephrine at time 1 (r = +.411, p < .06) and with standing (r = +.400, p < .08).
To evaluate the possible effects at time 1 of standing norepinephrine and gender on the group differences in clonidine Bmax, MANOVA were performed. Including clonidine Bmax and standing norepinephrine for patients vs. all other subjects, the overall MANOVA was significant (p = .05); in this MANOVA, norepinephrine was significantly different across groups (p < .04), and there was a trend for Bmax (p < .08). In a similar MANOVA, but also including gender as a between-subject factor, the overall MANOVA remained significant for patients vs. other subjects (p < .04) but was not significant for gender; norepinephrine was slightly more strongly significant (p < .03), and a more robust trend was observed for Bmax (p < .06). Thus, differences between patients vs. other subjects in norepinephrine level produced only a small effect on the difference in clonidine binding in patients vs. asymptomatic individuals.
To further assess the relationship between variables found individually to be of significance, multiple regressions were performed using standing norepinephrine and symptom rating (Ham-A) to predict clonidine Bmax at time 1. These regressions were performed for all subjects, for patients only, and for all other subjects only (Table 6 ). When all subjects and both independent variables were included, the multiple regression was significant, and norepinephrine was a more strongly associated predictor than symptoms. In the multiple regression including patients only, the overall regression was of greater magnitude than the regression for all subjects (but Psychosomatic Medicine 58:289-301 (1996) was not significant because of the smaller number of subjects); the partial r for symptoms showed a trend toward significance, and the partial r for norepinephrine was much weaker. In contrast, in the multiple regression including other subjects only (nonpatients), the overall multiple-R was of comparable magnitude to the multiple regression for all subjects (again not significant because of the smaller number of subjects), but the partial r for norepinephrine approached significance, and the partial r for symptoms was very weak. For all three groups (all subjects, patients only, and nonpatients only), the correlations between standing norepinephrine and symptoms were very weak. These results suggest that symptoms and standing norepinephrine make separate, independent contributions to the prediction of clonidine binding and that the two variables are relevant in different populations. In patients, symptoms were a strong predictor, and standing norepinephrine was less important, but standing norepinephrine was a fairly strong predictor, and symptoms made no contribution to prediction in nonpatients. There were no lying or standing norepinephrine differences for patients vs. control subjects at time 2. Across groups of patients receiving different treatments at time 2, there were significant differences in lying (p < .001, ANOVA) and standing (p < .01, ANOVA) norepinephrine; as expected, based on prior studies (9, 41, 42), the highest levels were for those patients who received a tricyclic drug. Tricyclic drugs produced approximately 60% increases in norepinephrine from time 1 to time 2; the other drugs produced smaller increases or small decreases. Hemodynamics Lying heart rate was higher in patients than in other subjects at time 1 (p < .05, ANOVA, Table 5 ), and lying diastolic blood pressure at time 1 showed a trend in the same direction (p < .06, ANOVA, Table 5 ). Unlike the standing norepinephrine data, relatives of patients showed no significant differences in hemodynamic variables from controls or relatives of controls. No other measurements were significantly different at any time, and generally there did not appear to be any systematic differences. For patients, there was an association between norepinephrine and heart rate; this association was not observed for the other groups nor was any other consistent pattern of association.
DISCUSSION
This study was designed to address three questions: a) Could the finding of decreased platelet a2-adrenergic receptor binding in people with active panic disorder be replicated? b) Do asymptomatic first-degree relatives of panic patients also have decreased binding? and c) Does the putative decreased binding in panic patients remain or normalize in response to effective treatment (ie, is this decreased binding a state or a trait abnormality in these patients)? Plasma catecholamine levels, hemodynamic variables, and anxiety symptoms were also evaluated in relation to these three questions.
Concerning the first question, in comparison to the nonsymptomatic individuals in the study, panic patients had a significantly decreased maximum number of binding sites (Bmax) for the partial agonist clonidine, although the effect only accounted for a small amount of the variance. The magnitude of this decrease was significantly negatively correlated with symptom severity, indicating that the most symptomatic patients had the greatest decreases in binding in comparison with asymptomatic individuals. No differences in the Bmax for the antagonist yohimbine or the Kd for either ligand were observed.
As described above, several groups have evaluated platelet a2-adrenergic receptor binding to platelets in panic disorder. We have reported decreases in two prior studies (9, 11), as has one other group (14, 19) , and other studies did not report differences (20, 21) . In one of our prior studies, only a decrease in yohimbine Bmax was observed (9), and in the other, decreases in binding for both ligands were seen (11). In the present study, a decrease in clonidine binding was seen, but the Bmax for yohimbine was not abnormal. A clear explanation for the discrepant results across studies is not apparent; differences in methodology (eg, ligand used) and characteristics of the subjects studied (eg, prior treatment history, presence and severity of comorbid disorders such as depression) are likely to account for at least part of the difference. In the three studies reported by our group, the results of each study were a little different, but in all three evidence for a decrease in platelet membrane a2-adrenergic receptor number was obtained. Two out of three of our studies showed decreases for yohimbine, and two of three showed decreases for clonidine. Of particular interest is the result with the clonidine because we are the only group that has systematically investigated agonist binding (9, 11, 22) .
It was observed that the binding measures for some of the normal subjects were unexpectedly low at time 1 in comparison with the results from our two prior studies, despite identical binding assay techniques (the binding parameters were more consistent with prior results for these subjects at times 2 and 3). It is not clear why this occurred. Because no verifiable explanation could be found to account for this result, these subjects were not excluded from the analysis. Had this unexpectedly low binding for some of the normal subjects not occurred, the difference between patients and nonsymptomatic individuals at time 1 would have been greater.
In addition to the finding of low clonidine Bmax at time 1 for some of the normal subjects, there was a "drift" in assay results (ie, across subjects studied at times 1 and 2, later results were higher than earlier results in normal subjects, in whom conditions across time did not change). This was partially, but not completely, explained by the unusually low binding for the subgroup of normal subjects described above. This is an important methodological issue; if we had not studied both experimental and control groups at the same time, it would not have been possible to determine that such assay "drift" had occurred. These differences might have been attributed erroneously to differences among groups. In all studies of this kind, all experimental groups should be evaluated simultaneously to avoid cohort effects. This is also of potential importance because there might be circannual changes in binding; this apparently has not been studied previously. Even if such a fluctuation exists, however, it should not affect our data because subjects in all four groups were studied over many months.
Standing norepinephrine levels at time 1 were higher for panic patients than for normal subjects and were negatively correlated with the number of binding sites for both ligands at time 1; the lying norepinephrine levels were not significantly different, but trends in the same direction for the negative correlation with the clonidine Bmax were observed for the lying norepinephrine levels (not shown). The negative relationship between standing norepinephrine and clonidine binding was present for both patients and nonpatients but was more robust for nonpatients. Lying heart rate was increased in patients, and a trend for increased lying diastolic blood pressure was observed; standing heart rate and standing diastolic blood pressure was also higher in patients but not significantly so. Norepinephrine levels were related to heart rate but only in patients.
These results are consistent with increased peripheral adrenergic activity in patients in this study. The result with norepinephrine is specifically consistent with the hypothesis that patients have normal basal levels but show increased reactivity to an adrenergic challenge (upright posture). Furthermore, the negative correlation between standing norepinephrine and binding is consistent with the hypothesis that catecholamine increases might produce "down-regulatory" decreases in clonidine binding. Against this interpretation, however: a) This negative correlation was not observed in our prior study (11); b) in the present study, the correlation was more robust for nonpatients than for patients; and (c) in general (as noted above), there have not been consistent findings concerning the status of systemic norepinephrine levels in panic patients. One possible explanation for the discrepant norepinephrine results reported previously might relate to the dynamics of norepinephrine release. For example, Stein et al. (12) found that norepinephrine levels 5 minutes after standing were normal in panic patients but that the heart rate increase was greater in patients. An inspection of their data (their Fig. 1 ) reveals that the heart rate increase (ie, the autonomic response) was apparent by 75 seconds after standing. In the present study, we measured standing norepinephrine 3 rather than 5 minutes after subjects stood. It is possible that patients, upon standing, released norepinephrine into the systemic circulation more rapidly than control subjects but did not attain a higher final level. In other words, reactivity was abnormal. A continuous multiple-sampling procedure will be needed to resolve this specific question, and, in general, in future studies investigators must attend closely to reactivity and timing issues and to determination of whether subjects have attained a reliable, stable baseline. As an example, despite efforts in the present study to obtain a valid basal lying catecholamine level, both patients and their relatives were slightly higher than the control subjects and their relatives (Fig. 1) . Although there are a number of possible reasons for this difference (including the possibility that it was due to chance variation only), it might reflect the fact that people with panic or people who are at risk for panic are in general more reactive to a wide variety of factors and situations.
Concerning the second question, there were no significant differences between binding parameters for normal subjects or their relatives compared with first-degree relatives of individuals with panic disorder. Furthermore, unlike the prior report of a significant correlation for the Bmax for yohimbine in dizygotic twins (43) , there were no significant correlations for any of the binding parameters for either patients or normal subjects with their respective first-degree relatives in this study.
Standing norepinephrine levels were elevated both in patients and in the asymptomatic relatives of patients in comparison with normal subjects and their relatives. It is known that these first-degree relatives of panic patients are at increased risk for the development of panic disorder, so these data suggest that the increase in plasma norepinephrine in response to a postural challenge might be a biological marker for risk of development of panic, at least in individuals with relatives who have the disorder. Although this finding was not hypothesized and the sample was small, and thus this finding must be interpreted cautiously, if valid it would be the first biological marker of people at risk but not symptomatic for an anxiety disorder. Such a marker would be extremely valuable for several kinds of studies because it would facilitate the prospective study of individuals perhaps most likely to develop panic before the presence of attacks themselves and before their sequellae confound interpretation of study results.
Concerning the third question, the difference in clonidine binding for patients vs. control subjects diminished over time in response to panic treatment, such that by time 3, binding for patients was actually higher than for normal subjects. There was no consistent pattern of change for the other binding parameters over the three times. These results suggest that binding might actually be increased in people with panic disorder when they do not have active panic in comparison with normal subjects but that the presence of the attacks themselves leads to a decrease in binding so that it appears that panic disorder produces a decrease in binding. Verification of the finding that binding is increased in panic disorder, independent of the occurrence of the attacks themselves and of possible drug effects on binding, will require further research.
Patients treated without medication showed a greater rise in the clonidine Bmax in response to treatment than did patients treated with one of the medications used. In contrast, treatment with tricyclic "antidepressant" drugs actually increased norepinephrine levels, as has been previously reported (9, 41, 42), and was associated with decreased clonidine binding, as we have reported previously (9). Unlike the present study, in this prior study, decreased yohimbine binding was also observed. However, in the prior study also, the effect of a tricyclic drug was greater for clonidine than for yohimbine binding. Anxiety symptoms decreased in response to treatment, but these decreases were not significantly correlated with the changes in clonidine Bmax.
In general, the number of binding sites (Bmax) for the two ligands was positively correlated within and across times 1 and 2. This indicates that the number of sites that bind clonidine is a relatively stable percentage of the total number of binding sites (ie, the number of sites that bind yohimbine). The exception was the Bmax for clonidine at time 2, which was only weakly correlated with the clonidine and yohimbine binding at time 1. This is consistent with the hypothesis that treatment has effects not on the total number of binding sites (in this study, the Bmax for yohimbine did not significantly change in response to treatment) but rather on the subpopulation of sites that are physiologically active (ie, "coupled" or "high affinity" sites, the clonidine sites) and thus perhaps more relevant to the pathophysiology of the active disorder.
As already noted, the decreased Bmax for clonidine observed in panic patients disappeared in response to treatment. Furthermore, first-degree relatives of panic patients did not have decreased binding. Together, these results are consistent with the conclusion that a decreased number of platelet membrane a2-adrenergic receptors is a state rather than a trait marker for panic disorder. Many prior studies (eg, 21, 44-46), but not all (eg, 47), have also demonstrated lower binding or functional activity of beta adrenergic receptors on lymphocytes in panic patients, and the results of one study have indicated that the beta adrenergic receptor is also a state marker of panic (3); in this prior study, however, the patients were never evaluated after treatment while drug free.
To summarize the answers to the three aims of this study: First, there is a decrease in the number of a2-adrenergic receptors for the partial agonist clonidine to platelet membranes in panic patients; this decrease is associated with anxiety severity and, to a lesser extent, to reactivity of systemic norepinephrine to an adrenergic challenge (standing). Second, asymptomatic relatives of panic patients have normal binding parameters but might have another abnormality of adrenergic function (that is, increased adrenergic reactivity to a postural challenge as indicated by a greater increase in norepinephrine). And, third, based on the normality of binding in relatives of patients and the increase in binding in response to treatment, the binding abnormality appears to be a state rather than a trait marker of panic disorder. In contrast to the evidence that the binding abnormality is a state marker, the finding of the increased standing norepinephrine in both panic patients and their at-risk relatives suggests that the standing norepinephrine increase, if replicated, might represent a trait marker for a panic diathesis.
Binding was not correlated with age, and gender was not found to be a significant contributor to binding. Menstrual cycle and time of year of study were not specifically controlled or addressed. Most prior studies indicate that age (36, (48) (49) (50) , gender (51), menstrual cycle (52) (53) (54) (55) , and circadian factors (36, 48) do not affect platelet a2-adrenoreceptor binding, although a few investigators have reported effects for age (56) , gender (48) , and menstrual cycle (48) . There do not appear to be any studies of potential circannual effects.
What might be the mechanism producing this abnormality in panic disorder? One prior genetic linkage study found no evidence for mutations in several gene loci for adrenergic receptors, including the a2-adrenergic receptor, in pedigrees of families with panic (57) . This result seems consistent with our finding that the binding abnormality is a state rather than a trait marker for panic. Furthermore, the finding that the abnormality in this study was for clonidine binding, but not for yohimbine binding, is consistent with the hypothesis that the abnormality is not for the total number of platelet receptors but rather for those that are functionally active. Finally, there were significant correlations of pretreatment clonidine binding with symptom severity and norepinephrine reactivity. All of these findings are consistent with the hypothesis that the platelet binding abnormality is associated with active panic disorder.
It seems unlikely that the status of a receptor on platelets could produce or cause panic attacks. Thus, it might seem that the decrease in clonidine binding is a result of panic rather than related to the pathophysiology or cause. Down-regulation of receptors secondary to increases in circulating catecholamines would be the likely mechanism (11, 36). The negative correlation of pretreatment binding with norepinephrine reactivity seen in this study for both patients and nonpatients is consistent with the hypothesis of down-regulation. Against this mechanism as a possible explanation for decreased binding in patients is the fact that our prior study did not find this inverse relationship (11), and prior research in general has produced ambiguous results concerning abnormalities of systemic catecholamine levels in panic (2, 11, 16). However, we have suggested previously that abnormalities of adrenergic reactivity have not been carefully evaluated in most prior research (2, 16). Thus, an abnormality of adrenergic reactivity, leading to intermittent increases in plasma catecholamines in panic patients either during panic attacks or at other times, and a consequent decrease in the number of platelet a2-adrenergic receptors could be the mechanism of this abnormality. Further research is needed concerning possible abnormalities of adrenergic reactivity in panic disorder.
Another possibility is that there is an abnormality of «2-adrenergic receptor function in the central nervous system that is causally related to the pathophysiology of panic and that the status of the platelet a2 -adrenergic receptor is correlated with this central nervous system abnormality. Thus, an important question is the relevance of the status of peripheral markers of a disorder to the central nervous system pathophysiology of the disorder. One marker of central nervous system adrenergic functioning, the growth hormone response to clonidine, has been shown repeatedly to be blunted in panic disorder (2). An issue of major importance would be to determine whether these two markers of a2-adrenergic receptor status in panic, one in the periphery and one in the central nervous system, are related to each other. An association of this kind would link the status of the platelet receptor directly to the pathophysiology of the disorder, rather than it being merely a result of panic.
Finally, for both research and clinical purposes, it would be very useful to have a marker of abnormal central nervous system functioning that is as easily accessible as the platelet, not only for panic disorder but also to study stress and other psychiatric disorders (58, 59 ). For example, many studies of platelet a2-adrenergic receptor binding and the growth hormone response to clonidine have already been reported in depression (60, 61) , but here also the potential relationship between these markers is not known. One final issue related to clonidine, both as a binding ligand and as a drug producing various physiological effects, is the observation that clonidine can react with nonadrenergic imidazoline receptors; thus, it is possible that whatever clonidine-associated abnormalities are observed in panic, depression, or other disorders might not be related to adrenergic or noradrenergic dysfunction (62) . 
